CD274 and neoplasm: Tumor-cell-associated biomarkers, including tumor mutation burden (TMB) and high microsatellite instability (MSI-H), are established prognostic indicators for EC immunotherapy, while the evidence for programmed cell death ligand 1 (PD-L1) as a marker in this context has led to disputed conclusions (6).